GSK3B and prostate carcinoma: β−catenin (CTNNB1) and GSK−3β are other co-regulators of Androgen receptor and phosphorylation of AR by GSK−3β which inhibit AR driven transcription, but in prostate cancer, the increase in the activity of AKT suppression of GSK−3β due to phosphorylation helps in PCa progression61.